Literature DB >> 7757333

Interleukin-6 expression in the skin of patients with lupus erythematosus.

W Nürnberg1, N Haas, D Schadendorf, B M Czarnetzki.   

Abstract

It has been proposed that interleukin-6 may play a role in the pathogenesis of autoimmune diseases like lupus erythematosus. We have therefore investigated the immunoreactivity of IL-6 in 32 skin biopsies of 23 patients suffering from chronic discoid lupus erythematosus (n = 16), subacute cutaneous lupus erythematosus (n = 5) and systemic lupus erythematosus (n = 5) as well as in uninvolved skin (n = 6) and in normal skin from healthy volunteers (n = 3). Increased immunohistochemical staining was detectable in 14 of 26 biopsies from lesional skin. The remaining biopsies from lesional, non-lesional and normal skin displayed only minimal or no reactivity, but 8 out of 12 lupus erythematosus patients had been pretreated with local or systemic antiinflammatory drugs. Irrespective of the LE subtype, immunolabelling was generally most intense in the basal layer of the epidermis, with additional intense suprabasal staining in sections from 2 of 5 SLE patients. Preferential production of IL-6 in the lower parts of the epidermis was confirmed by RNA in situ hybridization. No correlation was found between the deposition of immunoglobulins and complement at the dermo-epidermal junction and IL-6 expression in keratinocytes. These data suggest that IL-6 may be involved in LE although its exact role in the pathogenesis of the disease needs to be further elucidated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7757333     DOI: 10.1111/j.1600-0625.1995.tb00222.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  12 in total

Review 1.  Cytokines and systemic lupus erythematosus.

Authors:  G S Dean; J Tyrrell-Price; E Crawley; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

2.  Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.

Authors:  Sang-Cheol Bae; Young Ho Lee
Journal:  Clin Rheumatol       Date:  2018-02-05       Impact factor: 2.980

3.  The association between interleukin-6 polymorphisms and rheumatoid arthritis: a meta-analysis.

Authors:  Young Ho Lee; Sang-Cheol Bae; Sung Jae Choi; Jong Dae Ji; Gwan Gyu Song
Journal:  Inflamm Res       Date:  2012-03-18       Impact factor: 4.575

Review 4.  A meta-analysis of the association of IL-6 -174 G/C and -572 G/C polymorphisms with systemic lupus erythematosus risk.

Authors:  Zaixing Yang; Yan Liang; Baodong Qin; Renqian Zhong
Journal:  Rheumatol Int       Date:  2013-09-07       Impact factor: 2.631

5.  Interleukin (IL)-6 modulates transforming growth factor-β receptor I and II (TGF-βRI and II) function in epidermal keratinocytes.

Authors:  Lerin R Luckett-Chastain; Mackenzie L Cottrell; Bethany M Kawar; Michael A Ihnat; Randle M Gallucci
Journal:  Exp Dermatol       Date:  2017-03-08       Impact factor: 3.960

6.  Comparative efficacy and tolerability of sarilumab 150 and 200 mg in patients with active rheumatoid arthritis : A Bayesian network meta-analysis of randomized controlled trials.

Authors:  S-C Bae; Y H Lee
Journal:  Z Rheumatol       Date:  2018-06       Impact factor: 1.372

7.  Interleukin-6 promoter polymorphism -174 G/C is associated with nephritis in Portuguese Caucasian systemic lupus erythematosus patients.

Authors:  Maria José Santos; Diana Fernandes; Susana Capela; Jose Canas da Silva; João Eurico Fonseca
Journal:  Clin Rheumatol       Date:  2010-12-14       Impact factor: 2.980

8.  Functional FCGR3A 158 V/F and IL-6 -174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis.

Authors:  Young Ho Lee; Sang-Cheol Bae; Gwan Gyu Song
Journal:  Rheumatol Int       Date:  2014-04-12       Impact factor: 2.631

9.  IL-2, IL-5, TNF-α and IFN-γ mRNA expression in epidermal keratinocytes of systemic lupus erythematosus skin lesions.

Authors:  José Ronaldo M Carneiro; Hellen T Fuzii; Cristiane Kayser; Fernando L Alberto; Fernando A Soares; Emília I Sato; Luís Eduardo C Andrade
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

10.  Cytokines and Effector/Regulatory Cells Characterization in the Physiopathology of Cutaneous Lupus Erythematous: A Cross-Sectional Study.

Authors:  Silvia Méndez-Flores; Gabriela Hernández-Molina; Ana Bety Enríquez; David Faz-Muñoz; Yeraldin Esquivel; Carlos Pacheco-Molina; Janette Furuzawa-Carballeda
Journal:  Mediators Inflamm       Date:  2016-03-06       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.